Phosphoinositides are a minor class of short-lived membrane phospholipids that serve crucial functions in cell physiology ranging from cell signalling and motility to their role as signposts of compartmental membrane identity 1,2 . Phosphoinositide 4-phosphates such as phosphatidylinositol 4-phosphate (PI(4)P) and phosphatidylinositol 4,5-bisphosphate (PI(4,5)P 2 ) are concentrated at the plasma membrane, on secretory organelles 3 , and on lysosomes 4 , whereas phosphoinositide 3-phosphates, most notably phosphatidylinositol 3-phosphate (PI(3)P) 5 , are a hallmark of the endosomal system 1,2 . Directional membrane traffic between endosomal and secretory compartments, although inherently complex, therefore requires regulated phosphoinositide conversion. The molecular mechanism underlying this conversion of phosphoinositide identity during cargo exit from endosomes by exocytosis is unknown. Here we report that surface delivery of endosomal cargo requires hydrolysis of PI(3)P by the phosphatidylinositol 3-phosphatase MTM1, an enzyme whose loss of function leads to X-linked centronuclear myopathy (also called myotubular myopathy) in humans 6 . Removal of endosomal PI(3)P by MTM1 is accompanied by phosphatidylinositol 4-kinase-2α (PI4K2α)-dependent generation of PI(4)P and recruitment of the exocyst tethering complex to enable membrane fusion. Our data establish a mechanism for phosphoinositide conversion from PI(3)P to PI(4)P at endosomes en route to the plasma membrane and suggest that defective phosphoinositide conversion at endosomes underlies X-linked centronuclear myopathy caused by mutation of MTM1 in humans.
. Removal of endosomal PI(3)P by MTM1 is accompanied by phosphatidylinositol 4-kinase-2α (PI4K2α)-dependent generation of PI(4)P and recruitment of the exocyst tethering complex to enable membrane fusion. Our data establish a mechanism for phosphoinositide conversion from PI(3)P to PI(4)P at endosomes en route to the plasma membrane and suggest that defective phosphoinositide conversion at endosomes underlies X-linked centronuclear myopathy caused by mutation of MTM1 in humans.
X-linked centronuclear myopathy (XLCNM) is a severe congenital myopathy caused by mutations in MTM1 (ref. 6) . Patients with XLCNM suffer from defective muscle fibres due to disorganized membrane compartments and T-tubules 7 and are affected by severe hypotonia at birth, while the mildest surviving cases display muscle and non-muscle phenotypes 8 . MTM1 knockout mice are born below Mendelian ratios, and show progressive myopathy and growth impairment leading to early death 9 . Depletion of MTM1 in fruitflies causes endosomal accumulation of β1-integrin in developing muscles 10 , possibly because of defective phosphoinositide conversion at endosomes. Intracellular β1-integrin accumulations were indeed seen in endosomes of the MTM1-deficient XLCNM-patient fibroblast cell line H31 (Fig. 1a) and in MTM1-depleted HeLa cells (Fig. 1b and Extended Data Fig. 1a ). Re-expression of active MTM1 rescued β1-integrin accumulation in H31 cells (Fig. 1c) . Accumulations of β1-integrin in MTM1-depleted cells were immunopositive for recycling endosomal transferrin receptor (TfR) and late endosomal Rab7, but displayed limited overlap with early endosomal Rab5 and were negative for the trans-Golgi network marker Rab8 (Extended Data Fig. 1a ). These data suggest that MTM1 loss-of-function causes β1-integrin accumulation in late endosomes, possibly to facilitate their degradation. We hypothesized that defective cargo exit from endosomes may underlie the endosomal sequestration of β1-integrin in XLCNM-patient cells. Therefore, we analysed the distribution of TfR, a receptor that, following internalization, is recycled by exocytosis from endosomes to the plasma membrane 11 . TfR surface levels, but not the total TfR levels, were decreased in H31 cells. This was rescued by re-expression of MTM1 ( Fig. 1d and 
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Extended Data Fig. 1b) . Thus, MTM1 is required for efficient surface delivery of TfR, presumably by regulating exocytosis from endosomes. We directly monitored Tf exocytosis from endosomes by total internal reflection fluorescence (TIRF) microscopy. In fibroblasts from healthy controls, Tf-containing endosomal structures approached the plasma membrane before exocytic release of their Tf content. Exocytic fusion events were detected much less frequently in H31 cells ( Fig. 1e-g ), where Tf-loaded endosomes were largely immobile, a phenotype confirmed in cells from another patient with XLCNM (Extended Data Fig. 1c ).
To dissect MTM1 function, we knocked down its expression in HeLa cells. MTM1 loss led to a partial depletion of TfR from the plasma membrane, resulting in reduced Tf internalization upon MTM1 knockdown (MTM1-KD) that was proportional to the diminished TfR surface levels ( Fig. 2a and Extended Data Fig. 2a, b) . Internalization kinetics and TfR expression were unaltered (Extended Data Fig. 2c-f) . Thus, MTM1 is required for efficient surface delivery of cargo by mediating exocytosis from endosomes. Consistent with this hypothesis, exocytic fusion events were detected much less frequently in MTM1-depleted HeLa cells, where stalled endosomes that failed to fuse accumulated underneath the plasma membrane, a phenotype rescued by re-expression of active but not phosphataseinactive (C375S) 12 MTM1 ( Fig. 2b and Extended Data Fig. 2g -j). Stalled TfR-containing endosomes in MTM1-KD cells were accessible to internalized Tf ligand and distinct from surface TfR pools ( Fig. 2c and Extended Data Fig. 2i-j) . MTM1 depletion did not significantly affect degradative sorting of internalized epidermal growth factor (EGF), EGF receptor levels, secretion, or retrograde traffic of endocytosed cholera toxin B; nor did we detect overt effects on the number of LC3B-containing autophagosomes (Extended Data Fig. 3a-h ). These data suggest that MTM1 depletion does not lead to a general impairment of endosome function.
In the absence of MTM1, endosomal TfR was redistributed to the cell periphery or remained scattered throughout the cytoplasm instead of its usual perinuclear concentration (Fig. 2c, d and Extended Data Fig. 2j) . A similar, although less severe, phenotype was seen in cells depleted of the related phosphoinositide 3-phosphatase MTMR1 (ref. 6) , while knockdown of other MTMs was without effect (Extended Data Fig. 3i-k) . To investigate the effect of XLCNM-patient mutations on exocytosis, we re-expressed active MTM1, phosphatase-inactive MTM1 (C375S), or MTM1 constructs with XLCNM mutations in MTM1-depleted HeLa cells. Phosphatase-inactive or disease-associated MTM1 mutants were unable to restore normal TfR-endosome distribution (Fig. 2e) . These data identify MTM1 as a key factor for endosomal exocytosis, while defective exocytosis results from MTM1 dysfunction in cells from patients with XLCNM.
We characterized the nature of sub-plasma-membrane endosomes accumulating in MTM1-depleted cells. MTM1-KD cells incubated with horseradish-peroxidase-coupled Tf displayed an accumulation of tubular and horseshoe-shaped organelles typical of early and recycling endosomes 11 (Extended Data Fig. 2k-m) . TfR-positive endosomes often formed elongated membrane tubules ( Fig. 2c and Extended Data Fig. 4a ) and contained early and recycling endosomal markers such as early endosomal antigen 1 (EEA1), Rab4, Rab5, Rab11, and Rab14 (ref. 11) (Fig. 3a and Extended Data Fig. 4b-e) , and endosomal sorting nexins (SNXs) SNX1, SNX3, SNX4, SNX8, SNX17, and SNX27 (ref. 13) (Fig. 3a and Extended Data Fig. 5a, b) . Importantly, loss of MTM1 did not interfere with the segregation of endosomal compartments marked by distinct Rab proteins (Extended Data Fig. 4f, g ). TfRendosomes were negative for the Golgi marker GM130, endosomal APPL1, late endosomal/lysosomal LAMP1, retromer, the endocytic adaptor AP-2, Rab35, a marker for fast recycling, or SNX15 (Extended Data Figs 4b-d and 5a, b). In agreement with MTM1 acting on endosomes 12 , MTM1 co-localized with early and recycling endosomal markers, but much less with late endosomal or trans-Golgi network proteins (Extended Data Fig. 5c, d ).
As MTM1 is a PI(3)P 3-phosphatase that preferentially associates with PI(3)P (Extended Data Fig. 5e ), we investigated whether the sub-plasma-membrane accumulation of endosomes was caused by defects in phosphoinositide homeostasis. Titration of enhanced green fluorescent protein (eGFP)-2xFYVE of Hrs allowed the semiquantitative determination of PI(3)P levels in control and MTM1-depleted cells (Extended Data Fig. 6a ). Specificity was confirmed by applying the phosphoinositide 3-kinase inhibitor wortmannin and MTM1 overexpression (Extended Data Fig. 6b, d ). Loss of MTM1 resulted in a significant elevation of PI(3)P levels, whereas those of PI(4)P, PI(3,4)P 2 , and PI(4,5)P 2 remained unaltered ( Fig. 3b and Extended Data Fig. 6c) , consistent with ref. 12 . Endosomal PI(3)P accumulation in MTM1-depleted cells was also detected by the fluorescently labelled PX domain of p40 (Phox) 14 (Extended Data Fig. 6e , f) and was further enhanced by co-depletion of MTM1 and endosomal PI(3)P effectors SNX4 or SNX17 (Extended Data Fig. 6g, h ), suggesting that endosomal PI(3)P is partly masked by bound SNX4 and SNX17 and possibly other PI(3)P effectors. These data indicate that MTM1-mediated hydrolysis of PI(3)P on endosomes triggers loss of PI(3)P-associated proteins (that is, SNXs) as a prerequisite for exocytosis. 
To challenge this hypothesis, we investigated whether defects induced by MTM1 depletion can be counteracted by manipulating PI(3)P synthesis 5 . Co-depletion of the phosphoinositide 3-kinase Vps34 together with MTM1 largely rescued defective TfR distribution seen in MTM1-KD cells (Fig. 3c and Extended Data Fig. 6i ). Moreover, acute perturbation of PI(3)P synthesis by the selective Vps34-inhibitor Vps34-IN1 (ref. 15 ) restored defective Tf exocytosis and endosomal β1-integrin accumulation in MTM1-KD or XLCNM-patient cells (Fig. 3d-f and Extended Data Fig. 6j ). These data strengthen the close correlation between impaired PI(3)P hydrolysis due to MTM1 lossof-function and the strong disease pattern in patients with XLCNM, and open the possibility that defects in patients with XLCNM could be cured by pharmacological inhibition of Vps34 activity.
TfR dispersion in absence of MTM1 but not defective Tf exocytosis was also abrogated by knockdown of the PI(3)P-associated endosomal kinesin KIF16B (Extended Data Fig. 7a, b) , indicating that defective Tf exocytosis is not a secondary consequence of endosome repositioning in the absence of MTM1.
In vitro MTM1 in addition to PI(3)P can also act on PI(3,5)P 2 (ref. 16 ). By depleting the PI(3)P-selective 5-kinase PIKfyve, we simultaneously interfered with endosomal PI(3,5)P 2 synthesis and PI(3)P consumption as a substrate 1 . PIKfyve-KD did not restore perinuclear TfR-endosome localization or Tf exocytosis in MTM1-depleted cells. Instead, it mimicked the peripheral dispersion of TfR-endosomes seen in MTM1-KD cells, while co-depletion of both enzymes further aggravated endosomal defects evidenced by giant early endosome accumulation (Extended Data Fig. 7c-g ). To directly probe whether oversupply of PI(3)P is sufficient to impair endosomal exocytosis, we applied cellpermeable PI-derivatives. Addition of PI(3)P 17 , but not PI(4)P, impaired Tf exocytosis and led to TfR-endosome dispersion ( Fig. 3g-i ). We conclude that MTM1-mediated hydrolysis of endosomal PI(3)P is a prerequisite for surface delivery of cargo by exocytosis from endosomes.
To address whether following PI(3)P hydrolysis endosomes have to acquire another phosphoinositide identity before exocytosis, we monitored their phosphoinositide content by dual-colour live TIRF microscopy. PI(3)P-positive endosomes inevitably failed to fuse. In contrast, endosomes undergoing productive exocytosis frequently acquired PI(4)P, which was lost concomitantly with Tf during the fusion process ( Fig. 4a and Extended Data Fig. 8g ). PI(3,4)P 2 , PI(4,5)P 2 , or PI(3,4,5)P 3 displayed no association with fusing endosomes. Thus, endosomal exocytosis of Tf appears to be mediated by PI(4)P on endosomes.
A candidate for endosomal PI(4)P synthesis is PI4K2α, an enzyme localized to the trans-Golgi network 18 , endosomes 1, 19 , and secretory vesicles 3 where it regulates protein sorting 1 . MTM1 and PI4K2α co-localized on endosomes and associated with each other (Fig. 4b, d and Extended Data Fig. 9a ). In addition to myotubularin, quantitative mass spectrometry, together with affinity chromatography and co-immunoprecipitation, identified exocyst, an octameric PI(4)P-regulated complex 20 required for exocytosis, endosomal recycling 21 , and polarized sorting, as a binding partner of PI4K2α ( Fig. 4d and Extended Data Fig. 9a, b) , and both proteins co-localized on endosomes (Fig. 4c) . Furthermore, MTM1 associated with the Sec6 subunit of exocyst in yeast two-hybrid screens (not shown) and affinity chromatography (Extended Data Fig. 9c ). Thus, MTM1, PI4K2α, and exocyst may constitute a phosphoinositide conversion module for endosomal exocytosis.
Consistent with this hypothesis, depletion of PI4K2α or exocyst caused defects in endosomal exocytosis and a partial dispersion of TfR, akin to MTM1-KD or MTM1/PI4K2α double loss ( Fig. 4e and Extended Data Fig. 9d-i) . Exocyst recruitment to membranes is controlled by coincidence detection of PI(4)P and small GTPases 20 , for example Sec4 in yeast and Rab11 in mammals 22 . Consistently, depletion of either PI4K2α or Rab11a impaired both Tf exocytosis and exocyst recruitment to membranes (Fig. 4e-g and Extended Data Figs 8b-f and 10a-c). A PI(4)P requirement for exocyst recruitment was confirmed by overexpression of kinase-inactive PI4K2α, and application of membrane-permeant PI(4)P (Extended Data Fig. 10d , e). Endosomes undergoing productive exocytosis contained Rab11, while those positive for Rab5 inevitably failed to fuse (Extended Data Fig. 8a ). Taken together, PI(4)P produced by PI4K2α on Rab11-endosomes is required for recruitment of exocyst to enable endosomal exocytosis.
Finally, we analysed the effects of PI4K2α manipulation on membrane association of MTM1 and on PI(4)P and PI(3)P levels. Loss of PI4K2α impaired membrane recruitment of MTM1 (Fig. 4h) , while overexpression of active or inactive PI4K2α facilitated MTM1 NS, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001, unpaired twotailed t-test. a, f, h, Representative images from one of three independent experiments are shown. a, f, Scale bar, 10 μm; magnified insets, 1 μm. 
association with endosomes, resulting in PI(3)P depletion (Extended Data Fig. 10f, g ), consistent with the physical interaction of both proteins ( Fig. 4d and Extended Data Fig. 9a ). Furthermore, PI(3)P and PI(4)P were enriched in distinct endosomal subdomains, suggesting that conversion of PI(3)P to PI(4)P may be initiated at Rab5-positive endosomes (Extended Data Fig. 10h ). Importantly, PI4K2α-KD cells g, Reduced endosomal exocyst association in PI4K2α-depleted but not in MTM1-depleted cells revealed by confocal imaging (n = 3). h, Relative membrane-associated fraction of MTM1 in scr control or PI4K2α-depleted cells (n = 5). i, Relative levels of PI(3)P, PI(4)P, and PI(4,5)P 2 in PI4K2α-depleted HeLa cells (n = 7 for PI(3)P, n = 3 for all others). j, Model of phosphoinositide conversion during endosomal exocytosis. SE, sorting endosome; RE, recycling endosome; 2α, PI4K2α. n, number of independent experiments with one lysate (f, h), 15-30 images (g, i), or five videos (e) analysed per condition per experiment. Mean ± s.e.m.; NS, non-significant, *P < 0.05, **P < 0.01, ***P < 0.001, unpaired two-tailed t-test for immunocytochemistry (g, i) and live-TIRF (e), and one-sample t-test for western blot (f, h) quantifications. a-c, Representative images from one of four (b) or three (a, c) independent experiments are shown. b, c, Scale bar, 1 μm.
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not only contained reduced levels of PI(4)P but also accumulated PI(3)P on endosomes containing PI(3)P binding effectors ( Fig. 4i and Extended Data Fig. 10i-k) akin to MTM1 loss. Conversely, MTM1 was dispensable for the association of PI4K2α with TfR-endosomes (Extended Data Fig. 10l ), which is mediated by the endosomal SNARE cellubrevin/VAMP3 (ref. 23) .
Our results reveal a mechanism for phosphoinositide conversion at endosomes from PI(3)P to PI(4)P to enable exit from the endosomal system. Phosphoinositide conversion is probably initiated at Rab5-and PI(3)P-containing early endosomes, where MTM1-mediated hydrolysis of PI(3)P and concomitant PI(4)P synthesis by PI4K2α generates distinct recycling endosomal membrane domains destined for exocystdependent fusion with the plasma membrane (Fig. 4j) , a compartment enriched in PI(4)P 1, 24 . This phosphoinositide conversion mechanism is driven by coincident detection 2 as well as by reciprocal interactions among its components. These include the association of exocyst and its key regulators with PI4K2α and PI(4)P 20 and with MTM1, facilitation of membrane recruitment of MTM1 by PI4K2α, as well as association of MTM1 both with PI4K2α and with exocyst. A similar phosphoinositide conversion mechanism involving MTM1 and/or other myotubularin family members 6 may underlie cargo exit from endosomes towards PI(4)P-and PI(4,5)P 2 -containing lysosomes and autolysosomes. Importantly, our results indicate a close functional correlation between MTM1 depletion and XLCNM-patient mutations, and they suggest that defective phosphoinositide conversion at endosomes may account for the disturbed muscle morphology and impaired β1-integrindependent muscle attachment in developing muscle fibres in patients with XLCNM 6 . The fact that integrin localization defects in cells from patients with XLCNM can be reversed by application of Vps34 inhibitors 15 may offer a potential avenue to combat this devastating disease.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.

METHODS
No statistical methods were used to predetermine sample size. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. siRNAs. All siRNAs used in this study were 21-, 23-, or 27-base oligonucleotides including 3′-dTdT overhangs. For silencing, the following siRNAs were used targeting the human isoform: Exo70 5′-GGTTAAAGGTGACTGATTA-3′, MTM1 5′-GATGCAAGACCCAGCGTAA-3′, MTMR1 5′-GAGATAGTGTGCA AGGATA-3′, MTMR2 5′-GGACATCGATTTCAACTAA-3′, MTMR4 5′-CA GCATAGGTTACGGCAAA-3′, MTMR7 5′-TGCAAGAACTTTCAGATAA-3′, PI4K2α 5′-GGATCATTGCTGTCTTCAA-3′, Rab11a 5′-AAGAGC GATATCGAGCTATAA-3′, Sec3 5′-CCTGTTGGATATGGGAAACAT-3′, Sec6 5′-CTGGAGGCAGAGCATCAACAC-3′, SNX4 5′-TGGTCAGAG TGTCCTAACA-3′, SNX17 5′-CTGGCTTTTGAATACCTCA-3′, and Vps34 5′-CC CATGAGATGTACTTGAACGTAAT-3′. For silencing Kif16b and PIKfyve, a pool of four siRNAs was obtained from Dharmacon (Thermo Scientific). The scrambled control siRNA used throughout this study corresponded to the scrambled γ1 adaptin sequence 5′-AAATCGGATATCGGAATAG-3′. Plasmids. Complementary DNA encoding full-length human MTM1 and MTMR2 was provided by G. Di Paolo and inserted into a pcDNA3.1(+)-based haemagglutinin (HA)-, mCherry-, or eGFP-expression vector with tags at the amino (N) terminus of MTM1 and MTMR2. siRNA-resistant MTM1 constructs were created by introducing four silent mutations: 5′-gatgccaggcctagtgtaa-3′. P205L, R241L, Y397C, and C375S mutants of MTM1 were created by mutation of the respective amino acid of human MTM1. N-terminally tagged human MTMR7 and mouse MTMR1 were in a pcDNA3.1(+)-based vector backbone. N-terminally tagged GFP-MTMR4 was a gift from M. Clague, N-terminally tagged GFP-Rab4A and GFP-Rab11A were a gift from P. van Sluis, and GFP-Rab14 was provided by T. Proikas-Cezanne. N-terminally tagged GFP-Rab5A GFP-Rab8A and GFP-Rab35 were in the pEGFP-C vector backbone (Clonetech) and Rab5A in a pcDNA3.1(+) vector backbone. Q79L mutant of Rab5A was created by mutation of the respective amino acid of human Rab5A. Full-length human SNX1, SNX3, SNX4, SNX8, SNX15, SNX17, and SNX27 were inserted in a pcDNA3.1(+)-based expression vector to express N-terminally tagged eGFP-fusion proteins except for carboxy (C)-terminally tagged SNX17-eGFP. N-terminally tagged eGFP-2xFYVE-Hrs, eGFP-2xPH-PLCδ and eGFP-2xPH-FAPP1 were in a pcDNA3.1(+)-based expression vector. The mRFP-2xPH-TAPP1 was a gift from T. Takenawa and the eGFP-2xPH domain of Bruton's tyrosine kinase was a gift from M. Wymann. N-terminally tagged eGFP-mPI4K2α was in a pcDNA3.1(+)-based expression vector. N-terminally tagged HA-mPI4K2α was in the pcDNA5/FRT/TO expression vector (Life Technologies). D308A mutant of PI4K2α was created by mutation of the respective amino acid of mouse PI4K2α. To create N-terminally tagged GST-MTM1 and -Sec6, full-length human MTM1 and Sec6 were cloned in the Gateway pENTRA1 entry vector and by recombination transferred into the Gateway pGEX4T3 vector (Life Technologies). N-terminally tagged mouse PI4K2α was in the pGEX4T1 vector backbone. The B10-tag was engineered in-house by inserting the B10 epitope of the human oestrogen receptor in the pSG5 vector backbone (Stratagene) and used to create N-terminally tagged B10-MTM1 and B10-Sec6 (pSG5hERB10 empty vector). Cell lines. HeLa and COS-1 cells were from ATCC and not used beyond passage 30 from original derivation from ATCC without further authentication. Hek293 cells stably expressing HA-tagged mPI4K2α were generated using the FlpIn system developed by Life Technologies according to the manufacturer's protocol. The fibroblast cell line H31 from patients with XLCNM has a genomic deletion of the entire MTM1 (refs 27, 28); the fibroblast cell line G92-628 from a patient with XLCNM, referred to as XLCNM patient 2, has a stop mutation in MTM1 at amino acid 37 (refs 27, 28 All cell lines were routinely tested for mycoplasma contaminations on a monthly basis. siRNA and plasmid transfections. HeLa cells were transfected with siRNA using Oligofectamin (Life Technologies) according to the manufacturer's protocol. To achieve optimal knockdown efficiency, two rounds of silencing were performed. Cells were transfected on day 1, expanded on day 2, transfected for a second time on day 3, seeded for the experiment on day 4, and the experiment was performed on day 5. For transient overexpression of proteins in knockdown cells, plasmids were transfected on day 4 using Lipofectamin 2000 (Life Technologies) according to the manufacturer's protocol. In case of co-transfection of two plasmids, JetPrime (Polyplus) was used according to the manufacturer's protocol.
For transient overexpression of proteins in untreated cells, plasmids were transfected 24 h before analysis using Lipofectamin 2000 (Life Technologies).
For knockdown of transiently overexpressed proteins, cells were simultaneously transfected with plasmids and siRNA using Lipofectamin 2000 according to the manufacturer's protocol; expression was allowed overnight and cells analysed the next day.
HDFa, H31, and COS-1 cells were transfected using Lipofectamin 3000 (Life Technologies) according to the manufacturer's protocol; expression was allowed overnight and cells analysed the next day. Transferrin uptake and surface labelling. Cells seeded on coverslips coated with Matrigel (BD Biosciences) were serum-starved for 2 h and used for either Tf uptake or surface labelling.
For quantitative Tf uptake, cells were treated with 25 μg ml −1 Tf-Alexa647 (Life Technologies) for 10 min at 37 °C. After being washed twice with icecold phosphate-buffered saline (PBS), cells were acid washed at pH 5.3 (0.2 M Na-acetate, 0.2 M NaCl) for 1 min on ice to remove surface-bound Tf, followed by washing twice with ice-cold PBS and fixation with 4% paraformaldehyde (PFA) for 45 min at room temperature (23-25 °C) . For all immunocytochemistry stainings except MTM1 or Rab5 Q79L-expressing cells, inhibitor treatments (Wortmannin or Vps34-IN1), and staining of β1-integrin, cells were treated with 25 μg ml −1 Tf-Alexa647 (Life Technologies) for 30 min at 37 °C to allow Tf uptake to reach saturation. Cells were washed twice with PBS, followed by immunocytochemistry staining as described in Immunocytochemistry and spinning disc confocal imaging.
For TfR surface labelling, cells were incubated with 25 μg ml −1 Tf-Alexa647 for 45 min at 4 °C to block endocytosis, washed three times with ice cold PBS, and fixed with 4% PFA for 45 min at room temperature.
Tf uptake and surface labelling, and EGFR and LC3B labelling, were analysed using a Nikon Eclipse Ti microscope (eGFP filter set: F36-526; TexasRed filter set: F36-504; Cy5 filter set: F46-009; DAPI filter set: F46-000), equipped with a ×40 oil-immersion objective (Nikon), a sCMOS camera (Neo,Andor), and a 200 W mercury lamp (Lumen 200, Prior), operated by open-source ImageJ-based micromanager software and quantified using open-source ImageJ software. Levels of eGFR, LC3B, and internalized or surface-bound Tf were normalized to the cell area. The ratio of internalized Tf to surface-bound Tf was used to distinguish between uptake and recycling defects. Owing to small differences in TfR level in HDFa and H31 cells, surface-bound Tf was normalized to TfR level. TfR levels in HDFa and H31 cells were analysed by TfR antibody staining (see Immunocytochemistry and spinning disc confocal imaging) and analysed using a Nikon Eclipse Ti microscope as described above. Immunocytochemistry and spinning disc confocal imaging. Cultured cells seeded on Matrigel-coated coverslips were fixed for 10 min with 4% PFA, washed twice with PBS, permeabilized in blocking solution (10% goat serum, 20 mM Na x H x PO 4 pH 7.4, 0.3% Triton X-100, 100 mM sodium chloride) for 30 min, and incubated with primary antibodies diluted in blocking solution for 1 h. After three washes with washing solution (20 mM Na x H x PO 4 pH 7.4, 0.3% Triton X-100, 100 mM NaCl), secondary antibodies diluted in blocking solution were incubated for 1 h, followed by three washes in washing solution.
For transient overexpression of eGFP-MTM1, cells were washed twice with icecold PBS, incubated with PEM (80 mM Pipes pH 6.8, 5 mM EGTA, 1 mM MgCl 2 ) containing 0.05% saponin for 5 min at 4 °C, followed by a brief wash with icecold PEM. After fixation with 3% PFA for 15 min at 4 °C, cells were washed three times with PBS at room temperature, incubated with 50 mM NH 4 Cl for 10 min and washed again twice with PBS. Immunocytochemistry was done as described above with the exception that Triton X-100 was exchanged for 0.05% saponin in all buffers.
PI(3)P and PI(4)P stainings were performed as previously described 30 , although at a reduced concentration of eGFP-2xFYVE of 0.25 μg ml −1
. If indicated, PI(3)P was labelled using a GST-tagged Phox domain of p40 chemically conjugated to Alexa Fluor 488, which was a gift from I. Ganley. For wortmannin (SigmaAldrich) treatment, cells were incubated with 2 μm wortmannin (dissolved in dry dimethylsulfoxide (DMSO)) or DMSO, diluted in serum-free medium, for 30 min at 37 °C, and subsequent PI(3)P staining was performed as described above. PI(3,4)P 2 and PI(4,5)P 2 stainings were performed as previously described 31 . For all LC3 immunocytochemistry stainings, fresh serum-containing medium was added 2 h before fixation. In case of bafilomycin A1 (BafA1, Sigma-Aldrich) treatment cells were washed three times with HBSS and incubated with 100 nM BafA1 (dissolved in dry DMSO) diluted in HBSS for 3 h. Control cells were incubated with DMSO diluted in serum-containing medium. After fixation with 4% PFA for 30 min, cells were washed three times with PBS, permeabilized with 200 μg ml −1 digitonin diluted in PBS for 10 min, followed by three washes with PBS. Cells were incubated with the primary antibody diluted in PBS for 1 h, followed by three washes with PBS. Secondary antibodies diluted in PBS were incubated for 1 h, followed by three washes in PBS.
Protein and lipid immunocytochemistry stainings were routinely analysed and quantified using a spinning disc confocal microscope (Ultraview ERS, Perkin Elmer) with Volocity imaging software (Improvision, Perkin Elmer). For all quantifications, protein and lipid stainings were normalized to cell area. For quantification of TfR localization, cells with either perinuclear or peripheral TfR localization were counted. Peripheral TfR localization was defined as cells with either TfR dispersion or TfR accumulations at the cell periphery as shown in example images (Fig. 2c) , and the normalized fraction of cells with perinuclear TfR localization was quantified. The amount of co-localization between two channels was quantified using thresholded Pearson's correlation coefficients. To quantify the amount of co-localization at peripheral sites, thresholded Pearson's coefficients were calculated in three randomly chosen 100 pixel × 100 pixel squares in the cell periphery. For averaged line scans, line profiles were calculated as the mean fluorescence intensity averaged over 100 pixels. Maximum intensity projections were calculated from z-stacks with 200 nm spacing between slices covering the whole cell. For statistical analysis, see Statistical analysis of immunocytochemistry and live-cell TIRF experiments. Cholera toxin uptake. Cells seeded on Matrigel-coated coverslips were serumstarved for 30 min and treated with 1 μg ml −1 cholera toxin subunit B (Ctx) CF568 (Biotium) for 45 min at 37 °C, followed by 30 min chase in starvation medium. After being washed once with PBS, cells were fixed with 4% PFA for 30 min, washed twice with PBS, permeabilized in blocking solution (10% goat serum, 20 mM Na x H x PO 4 pH 7.4, 0.3% Triton X-100, 100 mM sodium chloride) for 15 min and incubated with primary antibody diluted in blocking solution for 30 min. After three brief washes with PBS, secondary antibody diluted in blocking solution was incubated for 30 min, followed by three brief washes in PBS. Secretion assay. C1 cells seeded on Matrigel-coated coverslips were washed once with PBS and treated with 1 μM D/D solubilizer (Clontech) diluted in HBSS to initiate secretion of the reporter construct. To halt secretion at the indicated time points, cells were placed on ice, washed twice with ice-cold PBS containing 10 mM MgCl 2 and fixed with 4% PFA for 20 min at room temperature, followed by washing twice with PBS. Secretion of the GFP-tagged reporter construct was analysed using a Nikon Eclipse Ti microscope (see Transferrin uptake and surface labelling). Fifteen minutes after initiating secretion the reporter is localized at the Golgi complex. To calculate the secretion from the Golgi, all time points were normalized to 15 min. TIRF microscopy. TIRF microscopy was performed using a Nikon Eclipse Ti microscope, equipped with an incubation chamber (37 °C), a ×60 TIRF objective (oil-immersion, Nikon), a sCMOS camera (Neo, Andor), a 200 W mercury lamp (Lumen 200, Prior), a triple-colour TIRF setup (laser lines: 488 nm, 568 nm, 647 nm), and operated by open-source ImageJ-based micromanager software. Cells seeded on Matrigel-coated coverslips were treated with 50 μg ml −1 Tf-Alexa647 (Life Technologies), diluted in serum-free medium for 30 min at 37 °C and 5% CO 2 . For analysis of transferrin exocytosis, time-lapse movies of 15-30 s with a frame rate of 5 Hz were recorded. For all time-lapse movies, the 488 nm channel was acquired before the 647 nm channel, except for Extended Data Fig. 9a , g. Fusion events with the plasma membrane were defined by their characteristic time course (appearance, broadening/spreading of the fluorescence signal, and disappearance), counted and normalized to cell area. Representative kymographs were chosen over 30 s along a line of 400 pixels in length. For statistical analysis, see Statistical analysis of immunocytochemistry and live-cell TIRF experiments. PIP/AM experiments. Cell-permeable acetoxy methylester (AM)-protected phosphatidylinositol derivatives were synthesized according to published procedures 17 . For treatment of cells, PI(3)P/AM and PI(4)P/AM were dissolved in dry DMSO and mixed with an equal volume of 10% pluronic F127 in DMSO (Sigma-Aldrich). PIP/AMs were diluted in serum-free medium to a final concentration of 100 μM. For immunocytochemistry stainings, cells seeded on Matrigel-coated coverslips were treated with DMSO + pluronic F127 (control) or PIP/AMs for 30 min at 37 °C and then processed as described above. For TfR immunocytochemistry stainings, cells were stimulated with 25 μg ml −1 Tf-Alexa647 during the PIP/AM treatment. For live-cell TIRF imaging, cells seeded on Matrigel-coated coverslips were treated with 25 μg ml −1 Tf-Alexa647 and DMSO + pluronic F127 (control) or PIP/AMs for 30 min at 37 °C, directly followed by live-cell imaging. Vps34-IN1 experiments. For the analysis of β1-integrin accumulations, H31 or HDFa cells were seeded on Matrigel-coated coverslips and treated with DMSO or Vps34-IN1 at a concentration of 0.01-1 μM dissolved in dry DMSO and diluted in serum-containing medium for 48 h, adding freshly diluted Vps34-IN1 or DMSO after 24 h. β1-integrin staining was performed as described in Immunocytochemistry and spinning disc confocal imaging.
For live-cell TIRF imaging (see Fig. 3d ), cells seeded on Matrigel-coated coverslips were treated with 50 μg ml −1 Tf-Alexa647 and DMSO or 1 μM VPS34-IN1 for 60 min at 37 °C, directly followed by live-cell imaging in the presence of DMSO or VPS34-IN1, respectively. I-labelled Tf in starvation medium at 37 °C for the indicated time points and washed twice on ice with PBS. Surface-bound 125 I-labelled Tf was removed by an acid wash with 0.2 M acetic acid, 0.5 M NaCl for 5 min on ice, collected, and radioactivity was measured using a scintillation counter (HIDEX 300SL). Cells were dried at room temperature for 5 min, lysed with 1 M NaOH for 60 min and the radioactivity of the lysate measured (corresponding to internalized Tf). Nonspecific binding was measured for each time-point in the presence of a 300-fold excess of cold Tf and was subtracted from all values. The ratio of internalized to surface-bound Tf was plotted over time and Michaelis constant (K m ) values were calculated using Prism software (GraphPad). Flow cytometry. On ice, cells were washed once with ice-cold PBS and detached from the culture dish by incubating for 5 min on ice with 0.1% PronaseE (SigmaAldrich), 0.5 mM EDTA solution in PBS. Cells were resuspended in PBS, pelleted at 300 g for 5 min at 4 °C and fixed in 4% PFA, 4% sucrose in PBS for 20 min at room temperature. Ten times excess volume of blocking solution (0.05% Saponin, 0.01% BSA in PBS) was added, then cells were pelleted and resuspended in blocking solution. After 15 min primary antibody (mouse-anti-TfR) was added and incubated for an additional 1 h. After washing once with blocking solution, cells were incubated for 1 h with secondary antibody diluted in blocking solution, followed by washing once with 0.2% BSA in PBS. Cells were resuspended in 0.2% BSA in PBS and analysed by flow cytometry using a BD LSRFortessa. Membrane fractionation. Cells from a 100% confluent 10 cm cell culture dish were harvested in homogenization buffer (20 mM HEPES pH 7.4, 100 mM KCl, 2 mM MgCl 2 , 1 mM PMSF, 0.1% protease inhibitor cocktail) and homogenized using a European Molecular Biology Laboratory cell cracker (HGM; inner diameter 8.020 mm, ball diameter 8.004 mm, with 12 strokes), followed by three freezethaw cycles in liquid nitrogen. Total cell lysate was collected after centrifugation at 1,000 g for 5 min at 4 °C. To obtain the cytosolic fraction, total cell lysate was centrifuged at 100,000 g for 30 min at 4 °C, the supernatant was collected, and protein concentration and volume determined. The membrane pellet was washed once in homogenization buffer and collected in a volume corresponding to the volume of the cytosol fraction. Equal volumes of total cell lysate (minimal concentration LETTER RESEARCH 0.125 μg μl −1 , corresponding to minimal loading of 5 μg), membrane pellet, and cytosol fraction were loaded onto a 10% acrylamide gel for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting. Western blot development was done using a LI-COR Odyssey Fc imager, and western blot bands were quantified using Image Studio Lite Version 4.0 software (LI-COR). For Exo70, Sec3, Sec8, and MTM1, protein levels in the total cell lysate were normalized to actin, whereas protein levels in the membrane fraction were normalized to gadkin. The ratio of membrane to total cell lysate was used to quantify the membrane fraction of Exo70, Sec3, Sec8, and MTM1. All knockdown conditions were normalized to membrane fractions of the respective protein in scrambled siRNA-treated controls. Data are presented as mean values ± s.e.m. from five independent experiments (n). Statistical testing was performed using a one-sample t-test. Co-immunoprecipitation experiments. Expression of HA-tagged PI4K2α in stably transfected Hek FlpIn cells was induced overnight by addition of doxycylin. As a control, untransfected Hek FlpIn cells were used. Cells were harvested in lysis buffer (20 mM HEPES pH 7.4, 100 mM KCl, 2 mM MgCl 2 , 1 mM PMSF, 0.1% protease inhibitor cocktail, 1% Triton X-100) and incubated on ice for 30 min, followed by centrifugation at 43,500 g for 20 min at 4 °C. The supernatant was centrifuged again at 265,000 g for 15 min at 4 °C. HA-matrix beads (Covance, mouse-anti-HA.11) were used to immunoprecipitate HA-tagged PI4K2α. Protein (3-5 mg ml ) was loaded on 30 μl 1:1 washed HA-matrix beads slurry and incubated for 1 h at 4 °C on a rotating wheel. Beads were pelleted, washed twice with lysis buffer, followed by two washes with homogenization buffer, and bound protein was eluted in 60 μl 1× Laemmli sample buffer. Eluates were loaded onto a 10% acrylamide gel for SDS-PAGE followed by immunoblotting. Affinity chromatography/GST-pulldown assays. Pulldown assays using GST-tagged PI4K2α as a bait were performed as described previously 26 . For pulldown assays using GST-tagged MTM1 and Sec6, GST fusion proteins were expressed in Escherichia coli BL21 pRARE strain. For negative control, the empty pGEX4T3 vector (GST alone) was used. The induction of expression was performed with 1 mM IPTG at 16 °C for 14 h. Bacteria were lysed on ice by sonication in lysis buffer (50 mM Tris HCl pH7, 200 mM NaCl, 1 mM EDTA, 1 mM DTT, complete protease inhibitor cocktail (PIC, Roche)) supplemented with 1 mg ml −1 lysozyme, 1 mM PMSF, 0.1% sarcosyl, 0.5% Triton X-100, and then centrifuged at 15,000 g for 30 min. GST-tagged proteins were purified from bacterial lysates by incubation with Glutathione Sepharose 4B beads (GE Healthcare) for 1 h followed by extensive washing with lysis buffer plus 1 mM PMSF. In parallel, COS-1 cells expressing B10-MTM1, B10-SEC6, HA-PI4K2α, or corresponding controls were lysed with a buffer containing 20 mM HEPES-KOH pH 7.5, 200 mM NaCl, 0.5% Triton X-100, 10% glycerol, 4 mM DTT, 1 mM EDTA, and PIC by passage through 25-gauge needles. Insoluble material was removed by centrifugation at 11,000 g for 10 min. Twenty micrograms of the purified GST fusion proteins coupled to glutathione beads were then incubated with 350 μg of COS-1 cell extracts. After washing beads three times with a buffer containing 20 mM HEPES-KOH, 200 mM NaCl, 1 mM DTT, and PIC (pH 7.3), 10 μg of GST beads were analysed by electrophoresis on a 10% SDS-polyacrylamide gel. Bound B10-tagged MTM1 and Sec6 or HA-tagged PI4K2α were detected with a B10-specific antibody or a PI4K2α-specific antibody, respectively. The entire procedure was performed at 4 °C, unless specified. Liposome flotation assay. Liposome flotation assays were performed in Hek293 cells as previously described 31 . Electron microscopy. Scrambled or MTM1 siRNA transfection was performed as described in HeLa cells that were grown in 6 cm plastic dishes. Cells were serumstarved for 2 h and treated with 25 μg ml −1 transferrin-HRP (Fitzgerald) for 30 min at 37 °C. Cells were fixed with 2% glutaraldehyde in PBS. After rinsing in fresh PBS, cells were mechanically detached by scratching, pelleted, and embedded into gelatine. After osmification with aqueous 1% osmium tetroxide, samples were stained en bloc with 1% aqueous uranil acetate and embedded in epoxy resin. Sections were viewed with Zeiss 910 transmission electron microscope and micrographs were taken along the cell perimeter at ×20,000. For morphometric analysis, images were combined to reconstruct the perimeter of a cell. The size and number of transferrin-HRP-labelled organelles up to 1 μm distance from the plasma membrane were quantified. The number of Tf-HRP endosomes was normalized to the plasma membrane perimeter. Ten cells per condition were analysed. To calculate the size of Tf-HRP endosomes, 52 endosomes for scrambled siRNA-treated controls and 90 endosomes for MTM1-depleted cells from a total of 10 cells were analysed. Data are presented as mean values ± s.e.m. A statistical test was performed using a one-sample t-test. Statistical analysis of immunocytochemistry and live-cell TIRF experiments. For analysis of immunocytochemistry experiments, a minimum of three independent experiments (n) was performed and statistically significant estimates for each sample were obtained by choosing an appropriate sample size, correlating to 15-30 images per condition per experiment for microscopy-based quantifications. Cells were chosen arbitrarily according to the fluorescent signal in a separate channel, which was not used for quantification. Data are presented as mean values ± s.e.m. For analysis of exocytic events per unit area in live-cell TIRF imaging experiments, a minimum of ten videos (duplicate coverslips: five videos per coverslip) per condition per experiment were acquired and fusion events were counted in minimally five videos per condition per experiment. A minimum of three independent experiments were performed and data represent mean values ± s.e.m. All statistical tests were performed using a two-tailed, unpaired t-test, without excluding samples from statistical analysis. . Accumulation of PI(3)P-binding SNXs (eGFP-tagged SNX1, SNX3, SNX4, SNX8, SNX17, SNX27) but not eGFP-tagged SNX15 on sub-plasma-membrane TfR endosomes in MTM1-KD cells. Scale bar, 10 μm; magnified insets, 1 μm. b, Quantification of co-localization between the indicated SNX protein and TfR in the cell periphery calculated using Pearson's correlation coefficient. Mean ± s.e.m., n = 3 independent experiments, unpaired two-tailed t-test. Numbers of images analysed: experiment 1 (scr: SNX4 n = 13, SNX15 n = 11, SNX17 n = 25; MTM1-KD: SNX4 n = 14, SNX15 n = 10, SNX17 n = 22); experiment 2 (scr: SNX4 n = 15, SNX15 n = 14, SNX17 n = 15; MTM1-KD: SNX4 n = 15, SNX15 n = 15, SNX17 n = 14); experiment 3 (scr: SNX4 n = 15, SNX15 n = 15, SNX17 n = 15; MTM1-KD: SNX4 n = 9, SNX15 n = 20, SNX17 n = 20). c, HeLa cells co-expressing eGFP-Rabs and mCherry-MTM1. Co-localization of MTM1 with early and recycling endosomal Rabs (Rab4, Rab5, Rab11, Rab14) is indicated by arrowheads. Scale bar, 2 μm. d, HeLa cells expressing eGFP-MTM1 were labelled for the indicated endosomal markers by specific antibodies. Arrowheads mark co-localization of MTM1 with the indicated proteins, whereas arrows mark MTM1-positive endosomes devoid of the indicated protein. Scale bar, 2 μm. e, Binding of HA-tagged MTM1 expressed in Hek293 cells to liposomes containing 5 mol% of the indicated phosphoinositide in flotation assays. MTM1 predominantly binds to PI(3)P-containing liposomes. Input, 30% (top) for bound and 15% (bottom) for unbound fractions. For blot source data, see Supplementary Fig. 1. a, c, d NS, non-significant, **P < 0.01, ***P < 0.001, unpaired two-tailed t-test.
